Vericel Co. (NASDAQ:VCEL) Stake Boosted by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Vericel Co. (NASDAQ:VCEL) by 22.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,773 shares of the biotechnology company’s stock after purchasing an additional 322 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Vericel were worth $77,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. International Assets Investment Management LLC boosted its holdings in shares of Vericel by 4,126.7% in the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 619 shares during the period. CWM LLC boosted its stake in Vericel by 319.0% in the second quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 504 shares during the period. Nisa Investment Advisors LLC grew its holdings in shares of Vericel by 9.7% during the second quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 220 shares during the last quarter. Lazard Asset Management LLC raised its position in shares of Vericel by 178.7% during the 1st quarter. Lazard Asset Management LLC now owns 2,584 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 1,657 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its position in Vericel by 104.9% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,108 shares of the biotechnology company’s stock valued at $188,000 after purchasing an additional 2,103 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on VCEL shares. Truist Financial raised their target price on Vericel from $56.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Stephens boosted their target price on shares of Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. BTIG Research dropped their price target on shares of Vericel from $56.00 to $55.00 and set a “buy” rating on the stock in a research note on Monday, July 15th. TD Cowen boosted their price objective on Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Finally, HC Wainwright increased their price objective on Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $57.71.

Insider Activity

In related news, Director Steven C. Gilman sold 5,833 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total transaction of $235,361.55. Following the completion of the transaction, the director now owns 11,000 shares of the company’s stock, valued at $443,850. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Vericel news, Director Steven C. Gilman sold 5,833 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total value of $235,361.55. Following the completion of the sale, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $443,850. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the transaction, the chief executive officer now directly owns 220,937 shares in the company, valued at $9,142,373.06. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,166 shares of company stock worth $1,200,764. 5.20% of the stock is owned by company insiders.

Vericel Price Performance

NASDAQ VCEL opened at $44.37 on Tuesday. The firm has a market capitalization of $2.18 billion, a PE ratio of -4,437,000.00 and a beta of 1.66. Vericel Co. has a 12 month low of $32.28 and a 12 month high of $54.10. The company’s 50 day simple moving average is $44.52 and its 200 day simple moving average is $46.30.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.